Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

PLA0178

Sigma-Aldrich

Rabbit anti-p16INK4a Antibody, Affinity Purified

Powered by Bethyl Laboratories, Inc.

Sinónimos:

ARF, CDK4 inhibitor p16-INK4, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS-1, MTS1, TP16, alternative reading frame, cell cycle negative regulator beta, cyclin-dependent kinase 4 inhibitor A, cyclin-dependent kinase inhibitor 2A (melanoma; p16; inhibits CDK4), multiple tumor suppressor 1, p14, p14ARF, p16, p16-INK4, p16INK4a, p19, p19Arf

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

100

antibody form

affinity purified immunoglobulin

antibody product type

primary antibodies

grade

Powered by Bethyl Laboratories, Inc.

species reactivity

human

concentration

0.2 mg/mL

technique(s)

immunohistochemistry: 1:100-1:500
immunoprecipitation (IP): 2-10 μg/mg
western blot: 1:2,000- 1:10,000

accession no.

AAA92554.1

shipped in

wet ice

storage temp.

2-8°C

target post-translational modification

unmodified

Gene Information

rabbit ... p16INK4a(1029)

General description

Cyclin-dependent kinase inhibitor 2A (CDK4I) or p16INK4a belongs to the Ink4 family of CDK inhibitors. The p16INK4agene is mapped to human chromosome 9p21. Structurally, p16INK4a comprises four ankyrin-type repeats (I–IV) .

Immunogen

The epitope recognized by PLA0178 maps to a region between residue 106 and 156 of human CDK4 inhibitor p16-INK4a using the numbering given in entry AAA92554.1 (GeneID 1029).

Biochem/physiol Actions

Cyclin-dependent kinase inhibitor 2A (CDK4I) or p16INK4a is a negative regulator of cyclin dependant kinase 4 (CDK4) and CDK6 kinase activity and cell cycle progression. The ankyrin repeats (I–IV) are crucial for their interaction with CDK4 and CDK6. P16INK4a regulates the cell cycle by inhibiting cyclin/CDK complex formation and the phosphorylation of the retinoblastoma protein (pRb). P16INK4a is a tumor suppressor and its mutations are associated with malignancies such as melanoma and astrocytoma and are the cause of Li-Fraumeni syndrome.

Physical form

Tris-buffered Saline containing 0.1% BSA containing 0.09% Sodium Azide

Other Notes

p16INK4a is a negative regulator of CDK4 and CDK6 kinase activity and cell cycle progression. P16INK4a regulates the cell cycle by inhibiting cyclin/CDK complex formation and the phosphorylation of the retinoblastoma protein (pRb). P16INK4a is a tumor suppressor associated with malignancies such as melanoma and astrocytoma and is the cause of Li-Fraumeni syndrome.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

¿No encuentra el producto adecuado?  

Pruebe nuestro Herramienta de selección de productos.

Storage Class

12 - Non Combustible Liquids

wgk_germany

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Cordula Windler et al.
Mechanisms of ageing and development, 164, 82-90 (2017-05-10)
Unmodified cells undergo only a limited number of cell divisions until they enter a state termed cellular senescence. Other triggers like cytotoxic compounds can also induce cell senescence. Since cell senescence represents a major mechanism of tumor suppression this cellular
Tomohito Tanaka et al.
PloS one, 12(5), e0177019-e0177019 (2017-05-05)
PD-0332991, the selective cyclin-dependent kinase 4/6 inhibitor palbociclib, causes cell cycle arrest by inhibiting phosphorylation of retinoblastoma (Rb) protein. The aim of this study was to evaluate the therapeutic potential of PD-0332991 in endometrial cancer. Four human endometrial cancer cell
Mayur A Gadhikar et al.
Cancer research, 78(3), 781-797 (2017-12-13)
Checkpoint kinase inhibitors (CHKi) exhibit striking single-agent activity in certain tumors, but the mechanisms accounting for hypersensitivity are poorly understood. We screened a panel of 49 established human head and neck squamous cell carcinoma (HNSCC) cell lines and report that
Johannes Nowak et al.
Clinical neuroradiology, 29(4), 595-604 (2018-07-22)
Epigenetic profiling has recently identified clinically and molecularly distinct subgroups of ependymoma. The 2016 World Health Organization (WHO) classification recognized supratentorial ependymomas (ST-EPN) with REL-associated protein/p65 (RELA) fusion as a clinicopathological entity. These tumors represent 70% of pediatric ST-EPN characterized by
Mariana López-Luppo et al.
Investigative ophthalmology & visual science, 58(7), 2832-2842 (2017-06-02)
Microaneurysms are present in healthy old-age human retinas. However, to date, no age-related pathogenic mechanism has been implicated in their formation. Here, cellular senescence, a hallmark of aging and several age-related diseases, has been analyzed in the old-age human retina
Ver todos los artículos relacionados

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico